Literature DB >> 22027876

Polymorphic mutations associated with the emergence of the multinucleoside/tide resistance mutations 69 insertion and Q151M.

Alexandra U Scherrer1, Viktor von Wyl, Matthias Götte, Thomas Klimkait, Cristina Cellerai, Sabine Yerly, Jürg Böni, Leonhard Held, Bruno Ledergerber, Huldrych F Günthard.   

Abstract

BACKGROUND: We hypothesized that polymorphic mutations exist that are associated with the emergence of the multinucleoside resistance mutations (MNR), 69 insertion and Q151M.
METHODS: The Swiss HIV Cohort Study was screened, and the frequencies of polymorphic mutations in HIV-1 (subtype B) were compared between patients detected with the 69 insertion (n = 17), Q151M (n = 29), ≥2 thymidine analogue mutations (TAM) 1 (n = 400) or ≥2 TAM 2 (n = 249). Logistic regressions adjusted for the antiretroviral treatment history were performed to analyze the association of the polymorphic mutations with MNR.
RESULTS: The 69 insertion and TAM 1 were strongly associated and occurred in 94.1% (16 of 17) together. The 69 insertion seemed to emerge as a consequence of the TAM 1 pathway (median years until detection: 6.8 compared with 4.4 for ≥2 TAM 1, P Wilcoxon = 0.009). Frequencies of 8 polymorphic mutations (K43E, V60I, S68G, S162C, T165I, I202V, R211K, F214L) were significantly different between groups. Logistic regression showed that F214L and V60I were associated with the emergence of Q151M/TAM 2 opposed to 69 insertion/TAM 1. S68G, T165I, and I202V were associated with Q151M instead of TAM 2.
CONCLUSIONS: Besides antiretroviral therapy, polymorphic mutations may contribute to the emergence of specific MNR mutations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22027876     DOI: 10.1097/QAI.0b013e31823c8b69

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  5 in total

1.  Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals.

Authors:  S Dimonte; M Babakir-Mina; S Aquaro; C-F Perno
Journal:  Infection       Date:  2013-04-26       Impact factor: 3.553

2.  Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.

Authors:  Anna Schneider; Angela Corona; Imke Spöring; Mareike Jordan; Bernd Buchholz; Elias Maccioni; Roberto Di Santo; Jochen Bodem; Enzo Tramontano; Birgitta M Wöhrl
Journal:  Nucleic Acids Res       Date:  2016-02-04       Impact factor: 16.971

3.  Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.

Authors:  Viktor von Wyl; Valentina Cambiano; Michael R Jordan; Silvia Bertagnolio; Alec Miners; Deenan Pillay; Jens Lundgren; Andrew N Phillips
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

4.  Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.

Authors:  Oliver T Stirrup; David T Dunn; Anna Tostevin; Caroline A Sabin; Anton Pozniak; David Asboe; Alison Cox; Chloe Orkin; Fabiola Martin; Patricia Cane
Journal:  AIDS Res Ther       Date:  2018-04-16       Impact factor: 2.250

5.  HIV Reverse Transcriptase and Protease Genes Variability Can Be a Biomarker Associated with HIV and Hepatitis B or C Coinfection.

Authors:  Natália Mirele Cantão; Lauana Fogaça de Almeida; Ivan Rodrigo Wolf; Rodrigo Oliveira Almeida; Andressa Alves de Almeida Cruz; Caroline Nunes; Alexandre Naime Barbosa; Guilherme Targino Valente; Maria Inês de Moura Campos Pardini; Rejane Maria Tommasini Grotto
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.